💡 Board approved a share buyback of up to 4.7 lakh shares at ₹1000 each, signaling confidence and returning capital to shareholders.
What Happened
The Board of Directors of Windlas Biotech Limited, in its meeting held on April 17, 2026, approved a proposal to buy back up to 4,70,000 fully paid-up equity shares of the company. This represents 2.23% of the total equity shares in the existing paid-up equity share capital. The buyback will be conducted through the tender offer route at a price of ₹1,000 per equity share, for an aggregate amount not exceeding ₹47 crore.
Key Details
- Company: Windlas Biotech Limited
- Event Type: Other
- Filing Date: 17-Apr-2026 14:09:35
- NSE Filing: View Document
Why It Matters
A share buyback is typically seen as a positive signal from a company's management, indicating they believe the stock is undervalued and that the company has sufficient cash reserves. By reducing the number of shares outstanding, earnings per share (EPS) can increase, potentially benefiting remaining shareholders. The board has also fixed Friday, April 24, 2026, as the record date to determine shareholder eligibility for the buyback, with the promoters and promoter group stating their intention not to participate.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free